Is this test available outside the US? Could I order the test?

Because we require live, fresh, cancer cells within 24-48 hours of doing a fine needle aspiration, we are ONLY offering our services in North America at this time. If you already had an experience of sending biopsy samples to the US in 24-48 hours, we could discuss the work further. Please contact info@imprimedicine.com.

Other Questions

Back to Help Center

What is a drug sensitivity test?

A drug sensitivity test is a lab test that measures how easily cells are killed by a drug.When you order a Personalized Prediction Profile, ImpriMed uses a proprietary high-throughput ex vivo drug sensitivity testing platform to analyze your patient’s live cells. For our canine leukemia and lymphoma service, we expose the cells to 13 different drugs commonly used to treat these diseases: L-Asparaginase, Mitoxantrone, Vincristine, Vinblastine, Doxorubicin, Rabacfosadine (Tanovea®), Chlorambucil, Mechlorethamine, Lomustine, Prednisolone (activated Prednisone), Mafosfamide (activated Cyclophosphamide), Melphalan, and Dexamethasone.-

How much research do you have to support your results?

All of our products are thoroughly validated in-house using clinical outcomes data and we have published multiple peer-reviewed papers demonstrating the efficacy of our predictions (Veterinary Sciences and Veterinary and Comparative Oncology). We have run over 12,000 tests on hematopoietic cells, and over 4,000 canine patients that have benefited from our services. We believe we have more data on canine lymphoma than any other company in the world.

What is the successful prediction rate for this test?

Positive predictive values for our AI-based drug response predictions are 80% or higher.

Does the veterinarian have to be the one to order the ImpriMed services?

No, any staff member affiliated with a veterinarian can submit or order via our portal so long as the leading veterinarian has an account setup.

What does the ImpriMed Personalized Prediction Profile include?

The Personalized Prediction Profile includes our Immunoprofile report and anticancer drug response predictions generated by artificial intelligence models. The predictions include estimates of both (1) the likelihood of a positive clinical response (partial response/ complete remission) to individual anticancer drugs and (2) the likelihood complete remission after 1 or 2 cycles of CHOP therapy, and the likelihood of early relapse after a successful CHOP regimen. Outcome predictions are currently provided for 13 individual drugs that are commonly used in many first-line and rescue protocols for the treatment of canine lymphoma (including CHOP, LOPP, MOPP, LPP, Tavonea only, etc…). Predictions are included for Doxorubicin, Cyclophosphamide, Vincristine, Vinblastine, Prednisone, Rabacfosadine (Tanovea®), L-Asparaginase, Lomustine, Mitoxantrone, Mechlorethamine, Dexamethasone, Chlorambucil, and Melphalan.